Search results
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
Zacks via Yahoo Finance· 1 year agoClovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy...
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 1 year agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 1 year agoClovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the...
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings...
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed...
What Kind Of Shareholders Own Clovis Oncology, Inc. (NASDAQ:CLVS)?
Simply Wall St. via Yahoo Finance· 2 years agoIf you want to know who really controls Clovis Oncology, Inc. (NASDAQ:CLVS), then you'll have to...
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Clovis Oncology (CLVS). Shares have lost...
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 22, 2022 – Stocks in this week’s article are Clovis...
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
